Risk factors for neoplastic progression in Barrett's esophagus

World Journal of Gastroenterology

Volumn 17, Issue 32, 2011, Pages 3672-3683

  Wiseman, Elizabeth F ^a   Ang, Yeng S ^a,b  

^a ROYAL ALBERT EDWARD INFIRMARY   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Barrett's esophagus; Esophageal adeno carcinoma; Metaplasia dysplasia carcinoma; Neoplastic progression; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; CHOLINERGIC RECEPTOR BLOCKING AGENT; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ALCOHOL CONSUMPTION; ANTIREFLUX OPERATION; ARTICLE; BARRETT ESOPHAGUS; CANCER GROWTH; CANCER RISK; CARCINOGENESIS; CHEMOPROPHYLAXIS; DIETARY INTAKE; ESOPHAGEAL ADENOCARCINOMA; ETHNICITY; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HEREDITY; HUMAN; MALIGNANT TRANSFORMATION; NONHUMAN; OBESITY; SEX DIFFERENCE; SMOKING; SOCIAL STATUS;

EID: 80053913871     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i32.3672     Document Type: Article

References (138)

1. Reid BJ. Barrett's esophagus and esophageal adenocarci-noma. Gastroenterol Clin North Am 1991; 20: 817-834
2. Hage M, Siersema PD, van Dekken H, Steyerberg EW, Dees J, Kuipers EJ. Oesophageal cancer incidence and mortality in patients with long-segment Barrett's oesophagus after a mean follow-up of 12.7 years. Scand J Gastroenterol 2004; 39: 1175-1179
3. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000; 119: 333-338
4. Jankowski JA, Provenzale D, Moayyedi P. Esophageal ad-enocarcinoma arising from Barrett's metaplasia has regional variations in the west. Gastroenterology 2002; 122: 588-590
5. Boulton RA, Usselmann B, Mohammed I, Jankowski J. Barrett's esophagus: environmental influences in the progression of dysplasia. World J Surg 2003; 27: 1014-1017
6. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70
7. Morales CP, Souza RF, Spechler SJ. Hallmarks of cancer progression in Barrett's oesophagus. Lancet 2002; 360: 1587-1589
8. Klump B, Hsieh CJ, Holzmann K, Gregor M, Porschen R. Hypermethylation of the CDKN2/p16 promoter during neo-plastic progression in Barrett's esophagus. Gastroenterology 1998; 115: 1381-1386
9. Arber N, Lightdale C, Rotterdam H, Han KH, Sgambato A, Yap E, Ahsan H, Finegold J, Stevens PD, Green PH, Hib-shoosh H, Neugut AI, Holt PR, Weinstein IB. Increased expression of the cyclin D1 gene in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 1996; 5: 457-459
10. Jankowski J, Hopwood D, Wormsley KG. Expression of epidermal growth factor, transforming growth factor alpha and their receptor in gastro-oesophageal diseases. Dig Dis 1993; 11: 1-11
11. Ireland AP, Clark GW, DeMeester TR. Barrett's esophagus. The significance of p53 in clinical practice. Ann Surg 1997; 225: 17-30
12. Wijnhoven BP, Tilanus HW, Dinjens WN. Molecular biology of Barrett's adenocarcinoma. Ann Surg 2001; 233: 322-337
13. Arber N, Gammon MD, Hibshoosh H, Britton JA, Zhang Y, Schonberg JB, Roterdam H, Fabian I, Holt PR, Weinstein IB. Overexpression of cyclin D1 occurs in both squamous carcinomas and adenocarcinomas of the esophagus and in adeno-carcinomas of the stomach. Hum Pathol 1999; 30: 1087-1092
14. Coppola D, Falcone R, Livingston S, Karl R, Nicosia S, Ca-cho CM. Cyclin D1 expression correlates with degrees of dysplasia in Barrett's esophagus. Lab Invest 1997; 76: 298-302
15. Umansky M, Yasui W, Hallak A, Brill S, Shapira I, Halpern Z, Hibshoosh H, Rattan J, Meltzer S, Tahara E, Arber N. Proton pump inhibitors reduce cell cycle abnormalities in Barrett's esophagus. Oncogene 2001; 20: 7987-7991
16. Song S, Krishnan K, Liu K, Bresalier RS. Polyphenon E inhibits the growth of human Barrett's and aerodigestive adenocarcinoma cells by suppressing cyclin D1 expression. Clin Cancer Res 2009; 15: 622-631
17. Singh SP, Lipman J, Goldman H, Ellis FH, Aizenman L, Cangi MG, Signoretti S, Chiaur DS, Pagano M, Loda M. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res 1998; 58: 1730-1735
18. Ellis FH, Xu X, Kulke MH, LoCicero J, Loda M. Malignant transformation of the esophageal mucosa is enhanced in p27 knockout mice. J Thorac Cardiovasc Surg 2001; 122: 809-814
19. Jankowski J, Coghill G, Tregaskis B, Hopwood D, Wormsley KG. Epidermal growth factor in the oesophagus. Gut 1992; 33: 1448-1453
20. Jankowski J, Murphy S, Coghill G, Grant A, Wormsley KG, Sanders DS, Kerr M, Hopwood D. Epidermal growth factor receptors in the oesophagus. Gut 1992; 33: 439-443
21. Jankowski J, Hopwood D, Wormsley KG. Flow-cytometric analysis of growth-regulatory peptides and their receptors in Barrett's oesophagus and oesophageal adenocarcinoma. Scand J Gastroenterol 1992; 27: 147-154
22. Yacoub L, Goldman H, Odze RD. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis. Mod Pathol 1997; 10: 105-112
23. Lanuti M, Liu G, Goodwin JM, Zhai R, Fuchs BC, Asoman-ing K, Su L, Nishioka NS, Tanabe KK, Christiani DC. A functional epidermal growth factor (EGF) polymorphism, EGF serum levels, and esophageal adenocarcinoma risk and outcome. Clin Cancer Res 2008; 14: 3216-3222
24. Konturek PC, Nikiforuk A, Kania J, Raithel M, Hahn EG, Mühldorfer S. Activation of NFkappaB represents the central event in the neoplastic progression associated with Barrett' s esophagus: a possible link to the infammation and over-expression of COX-2, PPARgamma and growth factors. Dig Dis Sci 2004; 49: 1075-1083
25. Herrera LJ, El-Hefnawy T, Queiroz de Oliveira PE, Raja S, Finkelstein S, Gooding W, Luketich JD, Godfrey TE, Hughes SJ. The HGF receptor c-Met is overexpressed in esophageal adenocarcinoma. Neoplasia 2005; 7: 75-84
26. Hardwick RH, Shepherd NA, Moorghen M, Newcomb PV, Alderson D. C-erbB-2 overexpression in the dysplasia/car-cinoma sequence of Barrett's oesophagus. J Clin Pathol 1995; 48: 129-132
27. Geddert H, Zeriouh M, Wolter M, Heise JW, Gabbert HE, Sarbia M. Gene amplification and protein overexpression of c-erb-b2 in Barrett carcinoma and its precursor lesions. Am J Clin Pathol 2002; 118: 60-66
28. Soslow RA, Ying L, Altorki NK. Expression of acidic fibro-blast growth factor in Barrett's esophagus and associated esophageal adenocarcinoma. J Thorac Cardiovasc Surg 1997; 114: 838-843
29. Soslow RA, Nabeya Y, Ying L, Blundell M, Altorki NK. Acidic fibroblast growth factor is progressively increased in the development of oesophageal glandular dysplasia and adenocarcinoma. Histopathology 1999; 35: 31-37
30. Kumble S, Omary MB, Cartwright CA, Triadaflopoulos G. Src activation in malignant and premalignant epithelia of Barrett's esophagus. Gastroenterology 1997; 112: 348-356
31. Iravani S, Zhang HQ, Yuan ZQ, Cheng JQ, Karl RC, Jove R, Coppola D. Modification of insulin-like growth factor 1 receptor, c-Src, and Bcl-XL protein expression during the progression of Barrett's neoplasia. Hum Pathol 2003; 34: 975-982
32. González MV, Artímez ML, Rodrigo L, López-Larrea C, Menéndez MJ, Alvarez V, Pérez R, Fresno MF, Pérez MJ, Sampedro A, Coto E. Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adeno-carcinoma. J Clin Pathol 1997; 50: 212-217
33. Barrett MT, Galipeau PC, Sanchez CA, Emond MJ, Reid BJ. Determination of the frequency of loss of heterozygosity in esophageal adenocarcinoma by cell sorting, whole genome amplification and microsatellite polymorphisms. Oncogene 1996; 12: 1873-1878
34. Kawakami K, Brabender J, Lord RV, Groshen S, Greenwald BD, Krasna MJ, Yin J, Fleisher AS, Abraham JM, Beer DG, Sidransky D, Huss HT, Demeester TR, Eads C, Laird PW, Ilson DH, Kelsen DP, Harpole D, Moore MB, Danenberg KD, Danenberg PV, Meltzer SJ. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocar-cinoma. J Natl Cancer Inst 2000; 92: 1805-1811
35. Younes M, Lebovitz RM, Lechago LV, Lechago J. P53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study. Gastroenterology 1993; 105: 1637-1642
36. Blount PL, Galipeau PC, Sanchez CA, Neshat K, Levine DS, Yin J, Suzuki H, Abraham JM, Meltzer SJ, Reid BJ. 17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy. Cancer Res 1994; 54: 2292-2295
37. Symmans PJ, Linehan JM, Brito MJ, Filipe MI. P53 expression in Barrett's oesophagus, dysplasia, and adenocarcinoma using antibody DO-7. J Pathol 1994; 173: 221-226
38. Rice TW, Goldblum JR, Falk GW, Tubbs RR, Kirby TJ, Casey G. P53 immunoreactivity in Barrett's metaplasia, dysplasia, and carcinoma. J Thorac Cardiovasc Surg 1994; 108: 1132-1137
39. Rioux-Leclercq N, Turlin B, Sutherland F, Heresbach N, Launois B, Campion JP, Ramee MP. Analysis of Ki-67, p53 and Bcl-2 expression in the dysplasia-carcinoma sequence of Barrett's esophagus. Oncol Rep 1999; 6: 877-882
40. Chung SM, Kao J, Hyjek E, Chen YT. p53 in esophageal ad-enocarcinoma: a critical reassessment of mutation frequency and identifcation of 72Arg as the dominant allele. Int J Oncol 2007; 31: 1351-1355
41. Hughes SJ, Nambu Y, Soldes OS, Hamstra D, Rehemtulla A, Iannettoni MD, Orringer MB, Beer DG. Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adeno-carcinoma. Cancer Res 1997; 57: 5571-5578
42. Mahidhara RS, Queiroz De Oliveira PE, Kohout J, Beer DG, Lin J, Watkins SC, Robbins PD, Hughes SJ. Altered traffck-ing of Fas and subsequent resistance to Fas-mediated apop-tosis occurs by a wild-type p53 independent mechanism in esophageal adenocarcinoma. J Surg Res 2005; 123: 302-311
43. van der Woude CJ, Jansen PL, Tiebosch AT, Beuving A, Homan M, Kleibeuker JH, Moshage H. Expression of apoptosis-related proteins in Barrett's metaplasia-dysplasia-carcinoma sequence: a switch to a more resistant phenotype. Hum Pathol 2002; 33: 686-692
44. Wilson KT, Fu S, Ramanujam KS, Meltzer SJ. Increased expression of inducible nitric oxide synthase and cyclooxy-genase-2 in Barrett's esophagus and associated adenocarci-nomas. Cancer Res 1998; 58: 2929-2934
45. Lagorce C, Paraf F, Vidaud D, Couvelard A, Wendum D, Martin A, Fléjou JF. Cyclooxygenase-2 is expressed frequently and early in Barrett's oesophagus and associated adeno-carcinoma. Histopathology 2003; 42: 457-465
46. Cheong E, Ivory K, Doleman J, Parker ML, Rhodes M, Johnson IT. Synthetic and naturally occurring COX-2 inhibitors suppress proliferation in a human oesophageal adenocarci-noma cell line (OE33) by inducing apoptosis and cell cycle arrest. Carcinogenesis 2004; 25: 1945-1952
47. Majka J, Rembiasz K, Migaczewski M, Budzynski A, Ptak-Belowska A, Pabianczyk R, Urbanczyk K, Zub-Pokrowiecka A, Matlok M, Brzozowski T. Cyclooxygenase-2 (COX-2) is the key event in pathophysiology of Barrett's esophagus. Lesson from experimental animal model and human subjects. J Physiol Pharmacol 2010; 61: 409-418
48. Morales CP, Lee EL, Shay JW. In situ hybridization for the detection of telomerase RNA in the progression from Barrett' s esophagus to esophageal adenocarcinoma. Cancer 1998; 83: 652-659
49. Lord RV, Salonga D, Danenberg KD, Peters JH, DeMeester TR, Park JM, Johansson J, Skinner KA, Chandrasoma P, De-Meester SR, Bremner CG, Tsai PI, Danenberg PV. Telomer-ase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg 2000; 4: 135-142
50. Barclay JY, Morris A, Nwokolo CU. Telomerase, hTERT and splice variants in Barrett's oesophagus and oesophageal ad-enocarcinoma. Eur J Gastroenterol Hepatol 2005; 17: 221-227
51. Shammas MA, Koley H, Batchu RB, Bertheau RC, Proto-popov A, Munshi NC, Goyal RK. Telomerase inhibition by siRNA causes senescence and apoptosis in Barrett's adeno-carcinoma cells: mechanism and therapeutic potential. Mol Cancer 2005; 4: 24
52. Couvelard A, Paraf F, Gratio V, Scoazec JY, Hénin D, De-gott C, Fléjou JF. Angiogenesis in the neoplastic sequence of Barrett's oesophagus. Correlation with VEGF expression. J Pathol 2000; 192: 14-18
53. Auvinen MI, Sihvo EI, Ruohtula T, Salminen JT, Koivistoin-en A, Siivola P, Rönnholm R, Rämö JO, Bergman M, Salo JA. Incipient angiogenesis in Barrett's epithelium and lymphan-giogenesis in Barrett's adenocarcinoma. J Clin Oncol 2002; 20: 2971-2979
54. Saad RS, El-Gohary Y, Memari E, Liu YL, Silverman JF. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma. Hum Pathol 2005; 36: 955-961
55. Griffiths EA, Pritchard SA, McGrath SM, Valentine HR, Price PM, Welch IM, West CM. Increasing expression of hy-poxia-inducible proteins in the Barrett's metaplasia-dyspla-sia-adenocarcinoma sequence. Br J Cancer 2007; 96: 1377-1383
56. Krishnadath KK, Tilanus HW, van Blankenstein M, Hop WC, Kremers ED, Dinjens WN, Bosman FT. Reduced expression of the cadherin-catenin complex in oesophageal adeno-carcinoma correlates with poor prognosis. J Pathol 1997; 182: 331-338
57. Washington K, Chiappori A, Hamilton K, Shyr Y, Blanke C, Johnson D, Sawyers J, Beauchamp D. Expression of beta-catenin, alpha-catenin, and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas. Mod Pathol 1998; 11: 805-813
58. Bailey T, Biddlestone L, Shepherd N, Barr H, Warner P, Jankowski J. Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation. Am J Pathol 1998; 152: 135-144
59. Jethwa P, Naqvi M, Hardy RG, Hotchin NA, Roberts S, Spychal R, Tselepis C. Overexpression of Slug is associated with malignant progression of esophageal adenocarcinoma. World J Gastroenterol 2008; 14: 1044-1052
60. Hughes SJ, Glover TW, Zhu XX, Kuick R, Thoraval D, Or-ringer MB, Beer DG, Hanash S. A novel amplicon at 8p22-23 results in overexpression of cathepsin B in esophageal ad-enocarcinoma. Proc Natl Acad Sci USA 1998; 95: 12410-12415
61. Cheng P, Gong J, Wang T, Chen J, Liu GS, Zhang R. Gene expression in rats with Barrett's esophagus and esophageal adenocarcinoma induced by gastroduodenoesophageal re-flux. World J Gastroenterol 2005; 11: 5117-5122
62. Breton J, Gage MC, Hay AW, Keen JN, Wild CP, Donnellan C, Findlay JB, Hardie LJ. Proteomic screening of a cell line model of esophageal carcinogenesis identifies cathepsin D and aldo-keto reductase 1C2 and 1B10 dysregulation in Barrett's esophagus and esophageal adenocarcinoma. J Proteome Res 2008; 7: 1953-1962
63. Lagorce-Pages C, Paraf F, Dubois S, Belghiti J, Fléjou JF. Expression of CD44 in premalignant and malignant Barrett's oesophagus. Histopathology 1998; 32: 7-14
64. Darlavoix T, Seelentag W, Yan P, Bachmann A, Bosman FT. Altered expression of CD44 and DKK1 in the progression of Barrett's esophagus to esophageal adenocarcinoma. Virchows Arch 2009; 454: 629-637
65. Leedham SJ, Preston SL, McDonald SA, Elia G, Bhandari P, Poller D, Harrison R, Novelli MR, Jankowski JA, Wright NA. Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett's oesophagus. Gut 2008; 57: 1041-1048
66. Maley CC, Galipeau PC, Li X, Sanchez CA, Paulson TG, Reid BJ. Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Res 2004; 64: 3414-3427
67. Paulson TG, Reid BJ. Focus on Barrett's esophagus and esophageal adenocarcinoma. Cancer Cell 2004; 6: 11-16
68. Ramel S. Barrett's esophagus: model of neoplastic progression. World J Surg 2003; 27: 1009-1013
69. Falk GW, Goldblum JR. Extent of low-grade dysplasia in Barrett's esophagus: is it useful for risk stratifcation? Am J Gastroenterol 2007; 102: 494-496
70. El-Serag HB, Mason AC, Petersen N, Key CR. Epidemiologi-cal differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA. Gut 2002; 50: 368-372
71. Corley DA, Kubo A, Levin TR, Block G, Habel L, Rumore G, Quesenberry C, Buffler P. Race, ethnicity, sex and temporal differences in Barrett's oesophagus diagnosis: a large community-based study, 1994-2006. Gut 2009; 58: 182-188
72. Wong A, Fitzgerald RC. Epidemiologic risk factors for Barrett's esophagus and associated adenocarcinoma. Clin Gas-troenterol Hepatol 2005; 3: 1-10
73. von Rahden BH, Stein HJ, Siewert JR. Barrett's esophagus and Barrett's carcinoma. Curr Oncol Rep 2003; 5: 203-209
74. Rogers EL, Goldkind SF, Iseri OA, Bustin M, Goldkind L, Hamilton SR, Smith RL. Adenocarcinoma of the lower esophagus. A disease primarily of white men with Barrett's esophagus. J Clin Gastroenterol 1986; 8: 613-618
75. Pondugula K, Wani S, Sharma P. Barrett's esophagus and esophageal adenocarcinoma in adults: long-term GERD or something else? Curr Gastroenterol Rep 2007; 9: 468-474
76. Kubo A, Corley DA. Marked multi-ethnic variation of esophageal and gastric cardia carcinomas within the United States. Am J Gastroenterol 2004; 99: 582-588
77. El-Serag HB, Petersen NJ, Carter J, Graham DY, Richardson P, Genta RM, Rabeneck L. Gastroesophageal reflux among different racial groups in the United States. Gastroenterology 2004; 126: 1692-1699
78. Vaezi MF, Richter JE. Synergism of acid and duodenogas-troesophageal reflux in complicated Barrett's esophagus. Surgery 1995; 117: 699-704
79. Nehra D, Howell P, Williams CP, Pye JK, Beynon J. Toxic bile acids in gastro-oesophageal reflux disease: infuence of gastric acidity. Gut 1999; 44: 598-602
80. Menges M, Müller M, Zeitz M. Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy. Am J Gastroenterol 2001; 96: 331-337
81. Theisen J, Nehra D, Citron D, Johansson J, Hagen JA, Crookes PF, DeMeester SR, Bremner CG, DeMeester TR, Peters JH. Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids. J Gastrointest Surg 2000; 4: 50-54
82. Wild CP, Hardie LJ. Reflux, Barrett's oesophagus and ad-enocarcinoma: burning questions. Nat Rev Cancer 2003; 3: 676-684
83. Qiao D, Gaitonde SV, Qi W, Martinez JD. Deoxycholic acid suppresses p53 by stimulating proteasome-mediated p53 protein degradation. Carcinogenesis 2001; 22: 957-964
84. Anderson LA, Watson RG, Murphy SJ, Johnston BT, Comber H, Mc Guigan J, Reynolds JV, Murray LJ. Risk factors for Barrett's oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. World J Gastroenterol 2007; 13: 1585-1594
85. Chak A, Faulx A, Eng C, Grady W, Kinnard M, Ochs-Balcom H, Falk G. Gastroesophageal reflux symptoms in patients with adenocarcinoma of the esophagus or cardia. Cancer 2006; 107: 2160-2166
86. Ouatu-Lascar R, Fitzgerald RC, Triadaflopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999; 117: 327-335
87. Attwood SE, Harrison LA, Preston SL, Jankowski JA. Esoph-ageal adenocarcinoma in & quot; mice and men& quot;: back to basics! Am J Gastroenterol 2008; 103: 2367-2372
88. Buttar NS, Wang KK. Mechanisms of disease: Carcinogene-sis in Barrett's esophagus. Nat Clin Pract Gastroenterol Hepatol 2004; 1: 106-112
89. Islami F, Kamangar F, Boffetta P. Use of proton pump inhibitors and risk of progression of Barrett's esophagus to neoplastic lesions. Am J Gastroenterol 2009; 104: 2646-2648
90. Obszynska JA, Atherfold PA, Nanji M, Glancy D, Santander S, Graham TA, Otto WR, West K, Harrison RF, Jankowski JA. Long-term proton pump induced hypergastrinaemia does induce lineage-specifc restitution but not clonal expansion in benign Barrett's oesophagus in vivo. Gut 2010; 59: 156-163
91. Ye W, Chow WH, Lagergren J, Yin L, Nyrén O. Risk of ade-nocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology 2001; 121: 1286-1293
92. Tran T, Spechler SJ, Richardson P, El-Serag HB. Fundoplica-tion and the risk of esophageal cancer in gastroesophageal reflux disease: a Veterans Affairs cohort study. Am J Gastro-enterol 2005; 100: 1002-1008
93. Corey KE, Schmitz SM, Shaheen NJ. Does a surgical antire-flux procedure decrease the incidence of esophageal adeno-carcinoma in Barrett's esophagus? A meta-analysis. Am J Gastroenterol 2003; 98: 2390-2394
94. Lagergren J, Bergström R, Adami HO, Nyrén O. Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med 2000; 133: 165-175
95. Maaroos HI, Vorobjova T, Sipponen P, Tammur R, Uibo R, Wadström T, Keevallik R, Villako K. An 18-year follow-up study of chronic gastritis and Helicobacter pylori association of CagA positivity with development of atrophy and activity of gastritis. Scand J Gastroenterol 1999; 34: 864-869
96. Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G. Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin Gastroenterol Hepatol 2007; 5: 1413-1417, 1417.e1-1417.e2
97. Weston AP, Badr AS, Topalovski M, Cherian R, Dixon A, Hassanein RS. Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GERD, Barrett's esophagus, Barrett's dysplasia, and Barrett's adenocarcinoma. Am J Gastroenterol 2000; 95: 387-394
98. Wu AH, Crabtree JE, Bernstein L, Hawtin P, Cockburn M, Tseng CC, Forman D. Role of Helicobacter pylori CagA+ strains and risk of adenocarcinoma of the stomach and esophagus. Int J Cancer 2003; 103: 815-821
99. Clemons NJ, McColl KE, Fitzgerald RC. Nitric oxide and acid induce double-strand DNA breaks in Barrett's esophagus carcinogenesis via distinct mechanisms. Gastroenterology 2007; 133: 1198-1209
100. Forman D, Al-Dabbagh S, Doll R. Nitrates, nitrites and gastric cancer in Great Britain. Nature 1985; 313: 620-625
101. Falk GW. Risk factors for esophageal cancer development. Surg Oncol Clin N Am 2009; 18: 469-485
102. Thomas T, Abrams KR, De Caestecker JS, Robinson RJ. Meta analysis: Cancer risk in Barrett's oesophagus. Aliment Pharmacol Ther 2007; 26: 1465-1477
103. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005; 143: 199-211
104. Cook MB, Greenwood DC, Hardie LJ, Wild CP, Forman D. A systematic review and meta-analysis of the risk of increasing adiposity on Barrett's esophagus. Am J Gastroenterol 2008; 103: 292-300
105. Kubo A, Corley DA. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2006; 15: 872-878
106. Murray L, Romero Y. Role of obesity in Barrett's esophagus and cancer. Surg Oncol Clin N Am 2009; 18: 439-452
107. de Jonge PJ, Steyerberg EW, Kuipers EJ, Honkoop P, Wolt-ers LM, Kerkhof M, van Dekken H, Siersema PD. Risk factors for the development of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol 2006; 101: 1421-1429
108. Oberg S, Wenner J, Johansson J, Walther B, Willén R. Barrett esophagus: risk factors for progression to dysplasia and adenocarcinoma. Ann Surg 2005; 242: 49-54
109. Vaughan TL, Kristal AR, Blount PL, Levine DS, Galipeau PC, Prevo LJ, Sanchez CA, Rabinovitch PS, Reid BJ. Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and fow cytometric abnormalities in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2002; 11: 745-752
110. Konturek PC, Burnat G, Rau T, Hahn EG, Konturek S. Effect of adiponectin and ghrelin on apoptosis of Barrett adenocarcinoma cell line. Dig Dis Sci 2008; 53: 597-605
111. Rubenstein JH, Dahlkemper A, Kao JY, Zhang M, Morgen-stern H, McMahon L, Inadomi JM. A pilot study of the association of low plasma adiponectin and Barrett's esophagus. Am J Gastroenterol 2008; 103: 1358-1364
112. Kendall BJ, Macdonald GA, Hayward NK, Prins JB, Brown I, Walker N, Pandeya N, Green AC, Webb PM, Whiteman DC. Leptin and the risk of Barrett's oesophagus. Gut 2008; 57: 448-454
113. Francois F, Roper J, Goodman AJ, Pei Z, Ghumman M, Mou-rad M, de Perez AZ, Perez-Perez GI, Tseng CH, Blaser MJ. The association of gastric leptin with oesophageal infamma-tion and metaplasia. Gut 2008; 57: 16-24
114. Ogunwobi O, Mutungi G, Beales IL. Leptin stimulates proliferation and inhibits apoptosis in Barrett's esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2-mediated transactivation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation. Endocrinology 2006; 147: 4505-4516
115. Dornonville de la Cour C, Lindström E, Norlén P, Håkan-son R. Ghrelin stimulates gastric emptying but is without effect on acid secretion and gastric endocrine cells. Regul Pept 2004; 120: 23-32
116. Mottershead M, Karteris E, Barclay JY, Suortamo S, New-bold M, Randeva H, Nwokolo CU. Immunohistochemical and quantitative mRNA assessment of ghrelin expression in gastric and oesophageal adenocarcinoma. J Clin Pathol 2007; 60: 405-409
117. de Martel C, Haggerty TD, Corley DA, Vogelman JH, Orent-reich N, Parsonnet J. Serum ghrelin levels and risk of subsequent adenocarcinoma of the esophagus. Am J Gastroenterol 2007; 102: 1166-1172
118. Kristal AR, Blount PL, Schenk JM, Sanchez CA, Rabinovitch PS, Odze RD, Standley J, Vaughan TL, Reid BJ. Low-fat, high fruit and vegetable diets and weight loss do not affect bio-markers of cellular proliferation in Barrett esophagus. Cancer Epidemiol Biomarkers Prev 2005; 14: 2377-2383
119. Terry P, Lagergren J, Hansen H, Wolk A, Nyrén O. Fruit and vegetable consumption in the prevention of oesophageal and cardia cancers. Eur J Cancer Prev 2001; 10: 365-369
120. Dong LM, Kristal AR, Peters U, Schenk JM, Sanchez CA, Rabinovitch PS, Blount PL, Odze RD, Ayub K, Reid BJ, Vaughan TL. Dietary supplement use and risk of neoplastic progression in esophageal adenocarcinoma: a prospective study. Nutr Cancer 2008; 60: 39-48
121. Chen H, Tucker KL, Graubard BI, Heineman EF, Markin RS, Potischman NA, Russell RM, Weisenburger DD, Ward MH. Nutrient intakes and adenocarcinoma of the esophagus and distal stomach. Nutr Cancer 2002; 42: 33-40
122. Rudolph RE, Vaughan TL, Kristal AR, Blount PL, Levine DS, Galipeau PC, Prevo LJ, Sanchez CA, Rabinovitch PS, Reid BJ. Serum selenium levels in relation to markers of neoplastic progression among persons with Barrett's esophagus. J Natl Cancer Inst 2003; 95: 750-757
123. Caygill CP, Johnston DA, Lopez M, Johnston BJ, Watson A, Reed PI, Hill MJ. Lifestyle factors and Barrett's esophagus. Am J Gastroenterol 2002; 97: 1328-1331
124. Gammon MD, Schoenberg JB, Ahsan H, Risch HA, Vaughan TL, Chow WH, Rotterdam H, West AB, Dubrow R, Stanford JL, Mayne ST, Farrow DC, Niwa S, Blot WJ, Fraumeni JF. Tobacco, alcohol, and socioeconomic status and adenocarci-nomas of the esophagus and gastric cardia. J Natl Cancer Inst 1997; 89: 1277-1284
125. Kabat GC, Ng SK, Wynder EL. Tobacco, alcohol intake, and diet in relation to adenocarcinoma of the esophagus and gastric cardia. Cancer Causes Control 1993; 4: 123-132
126. Zhang ZF, Kurtz RC, Sun M, Karpeh M, Yu GP, Gargon N, Fein JS, Georgopoulos SK, Harlap S. Adenocarcinomas of the esophagus and gastric cardia: medical conditions, tobacco, alcohol, and socioeconomic factors. Cancer Epidemiol Biomark-ers Prev 1996; 5: 761-768
127. Brown LM, Silverman DT, Pottern LM, Schoenberg JB, Greenberg RS, Swanson GM, Liff JM, Schwartz AG, Hayes RB, Blot WJ. Adenocarcinoma of the esophagus and esopha-gogastric junction in white men in the United States: alcohol, tobacco, and socioeconomic factors. Cancer Causes Control 1994; 5: 333-340
128. Vaughan TL, Davis S, Kristal A, Thomas DB. Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 1995; 4: 85-92
129. Menke-Pluymers MB, Hop WC, Dees J, van Blankenstein M, Tilanus HW. Risk factors for the development of an ad-enocarcinoma in columnar-lined (Barrett) esophagus. The Rotterdam Esophageal Tumor Study Group. Cancer 1993; 72: 1155-1158
130. Achkar JP, Post AB, Achkar E, Carey WD. Risk of extrae-sophageal malignancy in patients with adenocarcinoma arising in Barrett's esophagus. Am J Gastroenterol 1995; 90: 39-43
131. Gray MR, Donnelly RJ, Kingsnorth AN. The role of smoking and alcohol in metaplasia and cancer risk in Barrett's columnar lined oesophagus. Gut 1993; 34: 727-731
132. Levi F, Ollyo JB, La Vecchia C, Boyle P, Monnier P, Savary M. The consumption of tobacco, alcohol and the risk of ad-enocarcinoma in Barrett's oesophagus. Int J Cancer 1990; 45: 852-854
133. Lagergren J, Bergström R, Lindgren A, Nyrén O. The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. Int J Cancer 2000; 85: 340-346
134. Avidan B, Sonnenberg A, Schnell TG, Chejfec G, Metz A, Sontag SJ. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarci-noma. Am J Gastroenterol 2002; 97: 1930-1936
135. Smith KJ, O'Brien SM, Smithers BM, Gotley DC, Webb PM, Green AC, Whiteman DC. Interactions among smoking, obesity, and symptoms of acid reflux in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2005; 14: 2481-2486
136. Corley DA, Kerlikowske K, Verma R, Buffer P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003; 124: 47-56
137. Heath EI, Canto MI, Piantadosi S, Montgomery E, Wein-stein WM, Herman JG, Dannenberg AJ, Yang VW, Shar AO, Hawk E, Forastiere AA. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst 2007; 99: 545-557
138. Gatenby PA, Ramus JR, Caygill CP, Winslet MC, Watson A. Aspirin is not chemoprotective for Barrett's adenocarcinoma of the oesophagus in multicentre cohort. Eur J Cancer Prev 2009; 18: 381-384